Dr. Ligon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis Street
Boston, MA 02115Phone+1 617-732-5500
Summary
- Dr. Keith Ligon is Pathologist and Chief of Neuropathology at the MGB-Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA. He is affiliated with multiple hospitals in the area, including Mass General Brigham's Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Boston Children's Hospital. He received his medical degree from MD Anderson Cancer Center and McGovern Medical School at UTHealth and has been in practice 20 years. He specializes in neuropathology, anatomic pathology, pediatric pathology, and molecular diagnostics. He is experienced in oncologic pathology. He has more than 200 publications and over 500 citings.
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1997 - 2001
McGovern Medical School at UTHealthClass of 1997- Brigham and Women's HospitalFellowship, Neuropathology
Certifications & Licensure
MA State Medical License 2001 - 2025
American Board of Pathology Anatomic Pathology- American Board of Pathology Neuropathology
Clinical Trials
- Imatinib Mesylate in Treating Patients With Recurrent Meningioma Start of enrollment: 2003 Feb 01
- Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2005 Apr 01
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Start of enrollment: 2007 May 25
- Join now to see all
Publications & Presentations
PubMed
- A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek
Science Translational Medicine. 2025-02-19 - Genomic Profiling Reveals SMARCA4 Mutations Are Associated with Shorter Overall and Intracranial Progression-Free Survival in Patients with Melanoma Brain Metastases.Grant M Fischer, Nayan Lamba, Jayne Vogelzang, Ayal Aizer, Keith L Ligon
Clinical Cancer Research. 2025-02-17 - Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.Eudocia Q Lee, Brian M Alexander, Carlos G Romo, Jeffrey G Supko, Nathalie Y R Agar
Clinical Cancer Research. 2025-01-17
Journal Articles
- Immunophenotyping of Pediatric Brain Tumors: Correlating Immune Infiltrate with Histology, Mutational Load, and Survival and Assessing Clonal T Cell ResponseIsaac H Solomon, Mark W Kieran, Gabriel K Griffin, Pratiti Bandopadhayay, Jerome Ritz, Ashley S Plant, Keith L Ligon, Glenn Dranoff, Journal of Neuro-Oncology
Press Mentions
EMBARGOED: Study Reveals Activity of Navtemadlin in Glioblastoma, Points to Possible Treatment ImprovementsFebruary 19th, 2025- Weighing Cancer Cells Helps Predict Treatment OutcomesOctober 14th, 2021
- Cancer Drug Response and Outcome Predicted from Cell Mass ChangesOctober 7th, 2021
- Join now to see all
Grant Support
- Shared Resources CoreNational Cancer Institute2011–2012
- OLIG Function In CNS Development And TumorigenesisNational Institute Of Neurological Disorders And Stroke2006–2008
- OLIG Function In CNS Development And TumorigenesisNational Institute Of Neurological Disorders And Stroke2004–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
